The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| GHRS | +51% | N/A | N/A | -17% |
| S&P | +17.45% | +75.43% | +11.88% | +57% |
GH Research Plc operates as a holding company, which engages in the provision of biopharmaceutical products and services. It develops therapeutic products for patients of psychiatric and neurological disorders. The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Schönharting, and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$88.00K | -12.8% |
| Market Cap | $787.77M | 116.3% |
| Market Cap / Employee | $10.79M | 0.0% |
| Employees | 73 | 46.0% |
| Net Income | -$14,137.00K | -60.6% |
| EBITDA | -$16,611.00K | -29.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $246.25M | 144.3% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $147.00K | -60.2% |
| Short Term Debt | $365.00K | 43.1% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -20.26% | -1.5% |
| Return On Invested Capital | -11.62% | 11.2% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$12,273.74K | -28.5% |
| Operating Free Cash Flow | -$12,255.65K | -28.6% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.21 | 2.44 | 2.93 | 2.70 | 40.57% |
| Price to Tangible Book Value | 3.21 | 2.44 | 2.93 | 2.70 | 40.57% |
| Enterprise Value to EBITDA | -27.56 | -31.85 | -36.43 | -30.56 | 82.14% |
| Return on Equity | -16.2% | -16.3% | -17.9% | -21.0% | 7.46% |
| Total Debt | $658.00K | $647.00K | $582.00K | $512.00K | -17.95% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
